Skip to main content
. 2023 Jul 22;10(8):ofad390. doi: 10.1093/ofid/ofad390

Figure 2.

Figure 2.

Multiway sensitivity analyses comparing the strategies that use long-acting cabotegravir-rilpivirine with wraparound services (CAB-RPV/WS) and integrase inhibitor–based antiretroviral therapy without wraparound services (INSTI). Comparing CAB-RPV/WS with INSTI, we examined virologic suppression at 3 years (left) and life expectancy (right) when varying 3 parameters: non-HIV-related mortality (rows), mean loss to follow-up rate during wraparound services (y-axis), and efficacy of CAB-RPV at 3 months (x-axis). The base case is marked with an X. In all scenarios, CAB-RPV/WS would result in improved virologic suppression at 3 years (blue) and improved life expectancy (green) compared with INSTI. Abbreviations: CAB-RPV, long-acting injectable cabotegravir-rilpivirine; HIV, human immunodeficiency virus; INSTI, oral integrase inhibitor–based antiretroviral therapy; LTFU, loss to follow-up; PY-person-years; WS, wraparound services.